ストックスクリーナーアプリを入手
1.14
2.70%
0.03
アフターアワーズ：
1.15
0.01
+0.88%
An 2 Therapeutics Inc (ANTX) 最新ニュース
Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance
Medicenna Therapeutics Corp. - Baystreet.ca
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Yahoo Finance
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
Cardiol Therapeutics Inc. - Baystreet.ca
2025-02-16 | APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit | NDAQ:APLT | Press Release - Stockhouse Publishing
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - Yahoo Finance
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025 - Yahoo Finance
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - Yahoo Finance
Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - Yahoo Finance
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire
Apogee Therapeutics Announces First Patient Dosed in Part B - GlobeNewswire
Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire
Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
APLT Lead Plaintiff Deadline ApproachingContact Robbins LLP for Information About the Pending Class Action Against Applied Therapeutics, Inc. - The Malaysian Reserve
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - Yahoo Finance
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS - Investor Relations | Sarepta Therapeutics, Inc.
Dyne Therapeutics: Moving Forward On 2 Key Fronts - Seeking Alpha
Beam Therapeutics to Encore Data from BEACON Phase 1/2 - GlobeNewswire
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - Yahoo Finance
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial - Proactive Investors USA
Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - PR Newswire
BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer - Business Wire
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders - GlobeNewswire
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December - Defense World
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - MarketBeat
Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO. - Smartkarma
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - The Manila Times
Keros Therapeutics Halts Phase 2 PAH Trial Due to Safety Concerns, Maintains Q2 2025 Data Timeline - StockTitan
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - Yahoo Finance
Corvus Pharmaceuticals Announces Data from Cohort 2 of - GlobeNewswire
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - BioSpace
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - TipRanks
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Viking Therapeutics Launches Phase 2 Trial for Oral Weight Loss Drug After Impressive Early Results - StockTitan
Denali Therapeutics Announces Topline Results for Regimen G - GlobeNewswire
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics - Yahoo Finance
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation - Yahoo Finance
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential - StockTitan
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - The Manila Times
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Yahoo Finance
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Simply Wall St
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Applied Therapeutics, Inc. - The Malaysian Reserve
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire
0.22%
0.81%
大文字化:
|
ボリューム (24 時間):